Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 1/2005

01.01.2005 | Original Paper

Expression of e-cadherin in high-risk breast cancer

verfasst von: Eugene M. Howard, Stephen K. Lau, Robert H. Lyles, George G. Birdsong, Jay N. Umbreit, Ruby Kochhar

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Abstract

Purpose

E-cadherin expression is diverse, and differences in patient characteristics may produce variability in expression. Whereas some studies have indicated that downregulation of e-cadherin, associated with loss of cellular adhesiveness, was correlative with poor prognosis and metastasis, other studies have failed to confirm this. The present study uses a highly homogenous population of patients at high-risk for breast cancer, on the basis of ethnic and socio-economic status, to examine the relationship between e-cadherin and other prognostic markers in breast cancer.

Methods

Immunohistochemical staining was undertaken for estrogen (ER) and progesterone (PR) receptors, epidermal growth factor receptor 2 (Her-2), p53, vascular endothelial factor (VEGF), and hypoxia inducible factor 1α (HIF-1α) and the levels of these markers was compared to e-cadherin expression in a high-risk African-American patient population.

Results

E-cadherin expression persisted into the later stagers of the disease, and was strongly associated with Her-2 and HIF-1α expression, but not p53, ER/PR or VEGF.

Conclusions

In contrast to other studies on heterogeneous populations, e-cadherin is preserved in aggressive tumors in this high-risk population. The ethnic and socio-economic risk stratification needs to be accounted for in studies correlating markers and prognosis.
Literatur
Zurück zum Zitat Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R (1998) Hergulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 273:28238–28246CrossRefPubMed Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R (1998) Hergulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 273:28238–28246CrossRefPubMed
Zurück zum Zitat Asgeirsson KS, Jonasson JG, Tryggvaottir L, Olafsdottir K, Sigurgeirsdottir JR, Ingvarsson S, Ogmundsdottir HM (2000) Altered expression of e-cadherin in breast cancer: patterns, mechanisms and clinical significance. Eur J Cancer 36:1098–1106CrossRefPubMed Asgeirsson KS, Jonasson JG, Tryggvaottir L, Olafsdottir K, Sigurgeirsdottir JR, Ingvarsson S, Ogmundsdottir HM (2000) Altered expression of e-cadherin in breast cancer: patterns, mechanisms and clinical significance. Eur J Cancer 36:1098–1106CrossRefPubMed
Zurück zum Zitat Bankfalvi A, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G, Krech R, Lelle RJ, Boecker W (1999) Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopath 34:25–34CrossRef Bankfalvi A, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G, Krech R, Lelle RJ, Boecker W (1999) Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopath 34:25–34CrossRef
Zurück zum Zitat Bukholm IK, Nesland JM, Karensen R, Jacobsen U, Borresen-Dale AL (1997) Expression of e-cadherin and its relation to the p53 protein status in human breast carcinomas. Virchows Arch 431:317–321CrossRefPubMed Bukholm IK, Nesland JM, Karensen R, Jacobsen U, Borresen-Dale AL (1997) Expression of e-cadherin and its relation to the p53 protein status in human breast carcinomas. Virchows Arch 431:317–321CrossRefPubMed
Zurück zum Zitat Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Choux R, Lavaut M (1997) E-cadherin quantitative immunocytochemical assays in breast carcinomas. J Pathol 181:294–300CrossRefPubMed Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Choux R, Lavaut M (1997) E-cadherin quantitative immunocytochemical assays in breast carcinomas. J Pathol 181:294–300CrossRefPubMed
Zurück zum Zitat Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Beest P, Goovaerts G, Dirix LY, Van Dam P, Fox SB, Harris AL, Van Maarck EA (2003) Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong e-cadherin expression. Br J Cancer 88:718–725CrossRefPubMed Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Beest P, Goovaerts G, Dirix LY, Van Dam P, Fox SB, Harris AL, Van Maarck EA (2003) Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong e-cadherin expression. Br J Cancer 88:718–725CrossRefPubMed
Zurück zum Zitat D’Souza B, Taylor-Papdimitrou J (1994) Over-expression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-CD gene. Proc Natl Acad Sci 91:7202–7206PubMed D’Souza B, Taylor-Papdimitrou J (1994) Over-expression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-CD gene. Proc Natl Acad Sci 91:7202–7206PubMed
Zurück zum Zitat Elzagheid A, Kuopio T, Ilmen M, Collan Y (2002) Prognostication of invasive ductal breast cancer by quantification of e-cadherin immunostaining: the methodology and clinical relevance. Histopath 41:127–133CrossRef Elzagheid A, Kuopio T, Ilmen M, Collan Y (2002) Prognostication of invasive ductal breast cancer by quantification of e-cadherin immunostaining: the methodology and clinical relevance. Histopath 41:127–133CrossRef
Zurück zum Zitat Fearon ER (2003) Connecting estrogen receptor function, transcriptional repression, and e-cadherin expression in breast cancer. Cancer Cell 3:307–310CrossRefPubMed Fearon ER (2003) Connecting estrogen receptor function, transcriptional repression, and e-cadherin expression in breast cancer. Cancer Cell 3:307–310CrossRefPubMed
Zurück zum Zitat Gillett CE, Miles DW, Ryder K, Skilton D, Liebman RD, Springall RJ, Barnes DM, Hanby AM (2001) Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol 193:433–441CrossRefPubMed Gillett CE, Miles DW, Ryder K, Skilton D, Liebman RD, Springall RJ, Barnes DM, Hanby AM (2001) Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol 193:433–441CrossRefPubMed
Zurück zum Zitat Heimann R, Lan F, McBride R, Hellman S (2000) Separating favorable from unfavorable prognostic markers in breast cancer: the role of e-cadherin. Cancer Res 60:298–304PubMed Heimann R, Lan F, McBride R, Hellman S (2000) Separating favorable from unfavorable prognostic markers in breast cancer: the role of e-cadherin. Cancer Res 60:298–304PubMed
Zurück zum Zitat Jiang WG, Mansel RE (2000) E-cadherin complex and its abnormalities in human breast cancer. Surg Onc 9:151–171CrossRef Jiang WG, Mansel RE (2000) E-cadherin complex and its abnormalities in human breast cancer. Surg Onc 9:151–171CrossRef
Zurück zum Zitat Kemler R (1993) From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 9:317–321CrossRefPubMed Kemler R (1993) From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 9:317–321CrossRefPubMed
Zurück zum Zitat Kleer CG, van Golen KL, Braun T, Merajver SD (2001) Persistent e-cadherin expression in inflammatory breast cancer. Modern Path 14:458–463CrossRef Kleer CG, van Golen KL, Braun T, Merajver SD (2001) Persistent e-cadherin expression in inflammatory breast cancer. Modern Path 14:458–463CrossRef
Zurück zum Zitat Kochhar R, Howard EM, Tadros TS, Birdsong GG, Lyles RH, Lau SK (2003) Correlation of p53, her2neu, vascular endothelial growth factor (VEGF) and e-cadherin expression in adenocarcinoma of breast. Proc AACR 6213 Kochhar R, Howard EM, Tadros TS, Birdsong GG, Lyles RH, Lau SK (2003) Correlation of p53, her2neu, vascular endothelial growth factor (VEGF) and e-cadherin expression in adenocarcinoma of breast. Proc AACR 6213
Zurück zum Zitat Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, Giannopoulou I, Keramopoulos A, Davaris P, Pignatelli M (2002) Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopath 40:536–546CrossRef Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, Giannopoulou I, Keramopoulos A, Davaris P, Pignatelli M (2002) Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopath 40:536–546CrossRef
Zurück zum Zitat Palacios J, Benito N, Pizarro A, Limeres MA, Suarez A, Cano A, Gamallo C (1997) Relationship between ERBB2 and e-cadherin expression in human breast cancer. Virchows Arch 427:259–263 Palacios J, Benito N, Pizarro A, Limeres MA, Suarez A, Cano A, Gamallo C (1997) Relationship between ERBB2 and e-cadherin expression in human breast cancer. Virchows Arch 427:259–263
Zurück zum Zitat Parker C, Rampaul RS, Pinder SE, Bell JA, Wencyk PM, Blamey RW, Nicholson RI, Robertson JF (2001) E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer 85:1958–1963CrossRefPubMed Parker C, Rampaul RS, Pinder SE, Bell JA, Wencyk PM, Blamey RW, Nicholson RI, Robertson JF (2001) E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer 85:1958–1963CrossRefPubMed
Zurück zum Zitat Rose DP, Royak-Schaler, R (2001) Tumor biology and prognosis in black breast cancer: a review. Cancer Det Prev 25:16–31 Rose DP, Royak-Schaler, R (2001) Tumor biology and prognosis in black breast cancer: a review. Cancer Det Prev 25:16–31
Zurück zum Zitat Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of HIF-1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541–1545PubMed Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of HIF-1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541–1545PubMed
Zurück zum Zitat Zschiesche W, Schonborn I, Behrens J, Herrenknecht K, Hartveit F, Lilleng P, Birchmeier W (1997) Expression of e-cadherin and catenins in invasive mammary carcinomas. Anticancer Res 17:561–567PubMed Zschiesche W, Schonborn I, Behrens J, Herrenknecht K, Hartveit F, Lilleng P, Birchmeier W (1997) Expression of e-cadherin and catenins in invasive mammary carcinomas. Anticancer Res 17:561–567PubMed
Metadaten
Titel
Expression of e-cadherin in high-risk breast cancer
verfasst von
Eugene M. Howard
Stephen K. Lau
Robert H. Lyles
George G. Birdsong
Jay N. Umbreit
Ruby Kochhar
Publikationsdatum
01.01.2005
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2005
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-004-0618-z

Weitere Artikel der Ausgabe 1/2005

Journal of Cancer Research and Clinical Oncology 1/2005 Zur Ausgabe

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.